Phase II results of poziotinib in patients with heavily pretreated EGFR or HER2 exon 20–mutated NSCLC from WCLC 2018 reported by Clinical Care Options (CCO).
Results of ALTER1202 trial show significant PFS benefit with anlotinib for patients with SCLC who progressed after 2 lines of chemotherapy from WCLC 2018 reported by Clinical Care Options (CCO).
Entrectinib in ROS1-positive NSCLC showed substantial activity, even in patients with CNS metastases in an analysis of 3 early studies from WCLC 2018 reported by Clinical Care Options (CCO)
10-year mortality results from NELSON study in high-risk smokers followed with low-dose CT screening from WCLC 2018 reported by Clinical Care Options (CCO).
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.